TRxADE HEALTH (DB:4E40) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

4E40 Stoklara Genel Bakış

Operates as a health services information technology (IT) company in the United States.

4E40 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Risk Analizi

Earnings have declined by 49.8% per year over past 5 years

Does not have a meaningful market cap (€9M)

Negative shareholders equity

Shareholders have been substantially diluted in the past year

+ 1 daha fazla risk

TRxADE HEALTH, Inc. Rakipler

ifa systems

XTRA:IS8

€7.3m

DocCheck

XTRA:AJ91

€44.9m

MeVis Medical Solutions

XTRA:M3V

€44.4m

CompuGroup Medical SE KGaA

XTRA:COP

€724.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti TRxADE HEALTH
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$6.86
52 Haftanın En Yüksek Seviyesi	US$20.01
52 Haftanın En Düşük Seviyesi	US$0.0015
Beta	1.9
11 Aylık Değişim	0%
3 Aylık Değişim	70.70%
1 Yıllık Değişim	-65.69%
33 Yıllık Değişim	-88.95%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-90.85%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	4E40	DE Healthcare Services	DE Pazar
7D	0%	-0.009%	0.02%
1Y	-65.7%	-36.2%	19.6%

Getiri vs. Endüstri: 4E40 underperformed the German Healthcare Services industry which returned -10.2% over the past year.

Getiri vs Piyasa: 4E40 underperformed the German Market which returned 5.9% over the past year.

Fiyat Oynaklığı

Is 4E40's price volatile compared to industry and market?
4E40 volatility
4E40 Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	5.2%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 4E40's share price has been volatile over the past 3 months.

Zaman İçindeki Volatilite: Insufficient data to determine 4E40's volatility change over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2010	34	Suren Ajjarapu	www.trxadehealth.com

TRxADE HEALTH, Inc. Temel Bilgiler Özeti

TRxADE HEALTH'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
4E40 temel i̇stati̇sti̇kler
Piyasa değeri	€8.74m
Kazançlar(TTM)	-€3.49m
Gelir(TTM)	€8.83m

1.0x

P/S Oranı

-2.5x

F/K Oranı

4E40 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
4E40 gelir tablosu (TTM)
Gelir	US$9.43m
Gelir Maliyeti	US$4.16m
Brüt Kâr	US$5.27m
Diğer Giderler	US$9.00m
Kazançlar	-US$3.73m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.99
Brüt Marj	55.91%
Net Kâr Marjı	-39.55%
Borç/Özkaynak Oranı	0%

4E40 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company is no longer active

4E40 Stoklara Genel Bakış

Ödüller

Risk Analizi

TRxADE HEALTH, Inc. Rakipler

XTRA:IS8

€7.3m

XTRA:AJ91

€44.9m

XTRA:M3V

€44.4m

XTRA:COP

€724.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Scienture Inc. acquired TRxADE HEALTH, Inc. (NasdaqCM:MEDS) in a reverse merger transaction in a transaction valued at $103 Million.

TRxADE HEALTH, INC. Announces Special Cash Dividend, Payable on or About July 24, 2024

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Recent updates

Scienture Inc. acquired TRxADE HEALTH, Inc. (NasdaqCM:MEDS) in a reverse merger transaction in a transaction valued at $103 Million.

TRxADE HEALTH, INC. Announces Special Cash Dividend, Payable on or About July 24, 2024

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.061 loss per share (vs US$0.16 loss in 3Q 2021)

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.32 loss in 2Q 2021)

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2021)

No longer forecast to breakeven

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings released: US$0.65 loss per share (vs US$0.33 loss in FY 2020)

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)

Full year 2020 earnings released: US$0.33 loss per share (vs US$0.048 loss in FY 2019)

New 90-day high: €4.96

New 90-day low: €3.98

Third quarter earnings released

Trxade Group, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: €4.18

New 90-day low - €4.76

Trxade Group, Inc. to Report Q2, 2020 Results on Jul 27, 2020

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

TRxADE HEALTH, Inc. Temel Bilgiler Özeti

1.0x

-2.5x